Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/6191
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMuller, Jannis-
dc.contributor.authorSharmin, Sifat-
dc.contributor.authorLorscheider, Johannes-
dc.contributor.authorOzakbas, Serkan-
dc.contributor.authorKarabudak, Rana-
dc.contributor.authorHorakova, Dana-
dc.contributor.authorKalincik, Tomas-
dc.date.accessioned2025-05-25T19:24:27Z-
dc.date.available2025-05-25T19:24:27Z-
dc.date.issued2025-
dc.identifier.issn2168-6149-
dc.identifier.issn2168-6157-
dc.identifier.urihttps://doi.org/10.1001/jamaneurol.2025.0495-
dc.identifier.urihttps://hdl.handle.net/20.500.14365/6191-
dc.descriptionLugaresi, Alessandra/0000-0003-2902-5589; Foschi, Matteo/0000-0002-0321-7155en_US
dc.description.abstractImportance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main Outcome and Measure For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over >= 5 years). Results Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and Relevance Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.en_US
dc.description.sponsorshipSwiss Science Foundation [P500PM_214230, P5R5PM_225288]; National Health and Medical Research Council Investigator grants [2026836, 2033165]; MS Australia; Biogen; Novartis; Merck; Roche; Teva; Sanofi Genzymeen_US
dc.description.sponsorshipThe work was supported by grants from the Swiss Science Foundation (P500PM_214230 and P5R5PM_225288 to Dr Mueller) and by National Health and Medical Research Council Investigator grants (2026836 to Dr Kalincik and 2033165 to Dr Roos). Dr Roos is supported by a MS Australia postdoctora lfellowship grant. The MS Base Foundation is anot-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva,and Sanofi Genzymeen_US
dc.language.isoenen_US
dc.publisherAmer Medical Assocen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleStandardized Definition of Progression Independent of Relapse Activity (Pira) in Relapsing-Remitting Multiple Sclerosisen_US
dc.typeArticleen_US
dc.identifier.doi10.1001/jamaneurol.2025.0495-
dc.identifier.pmid40227706-
dc.identifier.scopus2-s2.0-105002792941-
dc.departmentİzmir Ekonomi Üniversitesien_US
dc.authoridLugaresi, Alessandra/0000-0003-2902-5589-
dc.authoridFoschi, Matteo/0000-0002-0321-7155-
dc.authorwosidSá, Maria/Agt-9846-2022-
dc.authorwosidSoysal, Aysun/Aax-7696-2021-
dc.authorwosidHorakova, Dana/D-4649-2011-
dc.authorwosidShaygannejad, Vahid/N-3495-2018-
dc.authorwosidOzakbas, Serkan/V-6427-2019-
dc.authorwosidRoos, Izanne/Abo-3767-2022-
dc.authorwosidLugaresi, Alessandra/C-7743-2012-
dc.authorscopusid56900313000-
dc.authorscopusid55028512500-
dc.authorscopusid54397364000-
dc.authorscopusid6602895100-
dc.authorscopusid6602766721-
dc.authorscopusid55053678000-
dc.authorscopusid6602736963-
dc.identifier.wosWOS:001470351300001-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.scopusqualityQ1-
dc.identifier.wosqualityQ1-
dc.description.woscitationindexScience Citation Index Expanded-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.grantfulltextnone-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.dept09.02. Internal Sciences-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.